Biotest AG
XETRA:BIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
40.8
42.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biotest AG
Biotest AG
Current Portion of Long-Term Debt
Biotest AG
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotest AG
XETRA:BIO
|
Current Portion of Long-Term Debt
€181.9m
|
CAGR 3-Years
174%
|
CAGR 5-Years
92%
|
CAGR 10-Years
38%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Current Portion of Long-Term Debt
€28.1m
|
CAGR 3-Years
67%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Current Portion of Long-Term Debt
€5.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Current Portion of Long-Term Debt
€5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
119%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Current Portion of Long-Term Debt
€2.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Current Portion of Long-Term Debt
€21.7m
|
CAGR 3-Years
180%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotest AG
Glance View
Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.
See Also
What is Biotest AG's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
181.9m
EUR
Based on the financial report for Sep 30, 2024, Biotest AG's Current Portion of Long-Term Debt amounts to 181.9m EUR.
What is Biotest AG's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
38%
Over the last year, the Current Portion of Long-Term Debt growth was 315%. The average annual Current Portion of Long-Term Debt growth rates for Biotest AG have been 174% over the past three years , 92% over the past five years , and 38% over the past ten years .
You don't have any saved screeners yet
